{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-23-000026","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.940040+00:00","generated_at":"2026-06-07T22:16:14.895189+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Editas Medicine amends severance plan, extending CEO benefits to 18 months post-change-of-control","bullets":["Amended plan extends change-in-control termination window to include 3 months prior to a change in control.","Non-change-in-control termination now includes term for Good Reason; requires termination >3 months prior to change.","CEO severance: base salary continuation extended to 18 months (was 12) and COBRA contributions also to 18 months.","Plan covers named executive officers and other designated employees under an unfunded welfare benefit plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-23-000026","json":"https://secwatch.observer/filing/0001650664-23-000026.json","markdown":"https://secwatch.observer/filing/0001650664-23-000026.md","text":"https://secwatch.observer/filing/0001650664-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066423000026/0001650664-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066423000026/edit-20231116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:16:14.895189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}